Gene Expressions and High Lymphocyte Count May Predict Durable Clinical Benefits in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.

Mette T Mouritzen,Morten Ladekarl,Henrik Hager,Trine B Mattesen, Julie B Lippert,Malene S Frank, Anne K Nøhr, Ida B Egendal,Andreas Carus

Cancers（2023）

引用 0|浏览4

暂无评分

摘要

ALC above 1.01 × 10/L and absence of liver metastases were significantly associated with DCB in ICI-treated patients with NSCLC. GEP was only feasible in 20% of the patients. GEP-derived signatures may be associated with clinical outcomes, and PD-L1 could be assessed by GEP rather than IHC.

查看译文

关键词

immune checkpoint inhibitors,lung cancer,high lymphocyte count may,non-small-cell

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要